LOINC
Version 2.73

39803-2inFLIXimab [Mass/volume] in Serum or PlasmaActive

Part Description

LP35095-6   inFLIXimab
Infliximab is a genetically engineered immunoglobulin 1 murine-human chimeric monoclonal antibody against tumor necrosis factor alpha (TNFα). The murine portion is the part of the antibody that binds to TNFα while the human portion preserves functional immune capacity. Infliximab is used to treat Crohn's disease and, in particular, in treating the closure of intestinal or perianal fistulas in patients with acute intestinal involvement who have been unresponsive to other treatments. TNFα is a cytokine that acts to increase the inflammatory process in CD, RA, psoriasis and spondylarthropathy. The primary mechanism of infliximab is to combine with the inactivate soluble transmembrane TNFα. However, infliximab also modulates TNFα-producing cells through complement fixation of antibody-dependent T lymphocytes and monocytes by binding them to the IgG1 fc portion of infliximab. There is also a subsequent down-regulation of other inflammation-producing cytokines and a reduction of the level of chemokines and endothelial adhesion molecules. Negative side effects of infliximab include fibrostenosing CD and sepsis.[PMID:18360638] Source: Regenstrief LOINC

Fully-Specified Name

Component
inFLIXimab
Property
MCnc
Time
Pt
System
Ser/Plas
Scale
Qn
Method

Additional Names

Short Name
inFLIXimab SerPl-mCnc
Display Name
inFLIXimab [Mass/Vol]
Consumer Name Alpha
inFLIXimab, Blood

Basic Attributes

Class
DRUG/TOX
Type
Laboratory
First Released
Version 2.15
Last Updated
Version 2.73
Order vs. Observation
Both
Common US Lab Results Rank
2646

Member of these Groups

LG16182-4 Infliximab|MCnc|Pt|ANYBldSerPl

Language Variants Get Info

zh-CNChinese (China)
英利昔单抗:质量浓度:时间点:血清/血浆:定量型:
nl-NLDutch (Netherlands)
infliximab:massa/volume:moment:serum of plasma:kwantitatief:
et-EEEstonian (Estonia)
Infliksimaab:MCnc:Pt:S/P:Qn:
fr-BEFrench (Belgium)
Infliximab:Concentration de masse:Temps ponctuel:Sérum/Plasma:Quantitatif:
fr-CAFrench (Canada)
Infliximab:Concentration de masse:Temps ponctuel:Sérum/Plasma:Quantitatif:
fr-FRFrench (France)
Infliximab:Masse/Volume:Ponctuel:Sérum/Plasma:Numérique:
de-DEGerman (Germany)
Infliximab:Massenkonzentration:Zeitpunkt:Serum oder Plasma:Quantitativ:
it-ITItalian (Italy)
Infliximab:MCnc:Pt:Siero/Plasma:Qn:
ko-KRKorean (Korea, Republic of)
Infliximab:질량농도:검사시점:혈청/혈장:정량:
pt-BRPortuguese (Brazil)
InfliximAc:MCnc:Pt:Sor/Plas:Qn:
ru-RURussian (Russian Federation)
Инфликсимаб:МассКонц:ТчкВрм:Сыв/Плаз:Колич:
es-MXSpanish (Mexico)
inFLIXimab:Concentración de masa:Punto temporal:Suero o Plasma:Cuantitativo:
es-ESSpanish (Spain)
Infliximab:Concentración de masa:Punto temporal:Suero o Plasma:Qn:
tr-TRTurkish (Turkey)
İnfliksimab:KütlKons:Zmlı:Ser/Plaz:Kant:

Example Units

Unit Source
ug/mL Example UCUM Units
mcg/mL REGENSTRIEF

LOINC FHIR® API Example - CodeSystem Request Get Info

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=39803-2